

Regional Technical Advisory Group (RTAG) for the Kala-azar Elimination Programme

Report of the Fifth Meeting Paro, Bhutan, 17-19 September 2013

SEA-CD-280 Distribution: General

Regional Technical Advisory Group (RTAG) for the Kala-azar Elimination Programme

Report of the fifth meeting Paro, Bhutan, 17–19 September 2013



Regional Office for South-East Asia

© World Health Organization 2013

All rights reserved.

Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Bookshop, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: sebookshop@searo.who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication does not necessarily represent the decisions or policies of the World Health Organization.

Printed in India

Contents

	Page	
Acro	nymsv	
Exec	utive summary vii	
1.	Opening session1	
2.	Objectives	
3.	On visceral leishmaniasis situation: global perspective and in the four countries of the Indian subcontinent2	
4.	On diagnosis of kala-azar4	
5.	On treatment	
6.	On post-kala azar dermal leishmaniasis7	
7.	On vector control	
8.	Supportive strategies: policy support and advocacy, partnership, resource mobilization, institutional support and cross-border collaboration9	
9.	On monitoring and evaluation11	
10.	Recommendations12	
Annexes		
1.	Agenda14	
2.	List of participants15	
3.	Message from Dr Samlee Plianbangchang, Regional Director WHO South-East Asia Region17	

Acronyms

ASHAs	accredited social health activists
DAT	direct agglutination test
DDT	dichlorodiphenyltrichloroethane
DNDi	drugs for neglected diseases initiative
EVM	environmental management
iOWH	one world health
IRS	indoor residual spraying
ISC	Indian subcontinent
ITNs	insecticide-treated nets
IVM	integrated vector management
КА	kala-azar
LAMB	liposomal amphotericin B
LAMP	loop-mediated isothermal amplification
LST	leishmanin skin testing
MoU	memorandum of understanding
MSF	Medicines sans Frontières
NTDs	neglected tropical diseases
PHC	primary health care
PKDL	post-kala-azar dermal leishmaniasis
QPCR	quantitative polymerase chain reaction
RDT	rapid diagnostic test

RTAG	Regional Technical Advisory Group
SEA	South-East Asia
SSG	sodium stibogluconate
TDR	Research and Training in Tropical Diseases
VL	visceral leishmaniasis
VL-HIV	visceral leishmaniasis-human immunodeficiency virus coinfection
WHO	World Health Organization

Executive summary

Kala-azar (KA) or visceral leishmaniasis (VL) is the second largest parasitic killer disease in the world after malaria and it is one of the most dangerous neglected tropical diseases (NTDs). The disease is prevalent in Bangladesh, India and Nepal in the WHO South-East Asia (SEA) Region. Recently, Bhutan started to report sporadic cases of KA. The disease affects the poorest communities in these countries and kills the patient if left untreated for a long time. Globally it is estimated that 200 000-400 000 new cases and 20 000-40 000 deaths occur every year. An estimated 147 million people in 119 districts in 4 countries, namely Bangladesh, Bhutan, India and Nepal, are at risk. India alone accounts for about 50% of the global burden. With little data on the burden of post-kala-azar dermal leishmaniasis (PKDL), surveillance needs to be established and/or strengthened for PKDL. The role of asymptomatic leishmania infection is not clear and further studies are needed. Diagnosis in past kala-azar cases, PKDL and asymptomatic infections, and test of cure are difficult as there are no tools currently available or the existing tools are not well standardized.

As recommended in the Fourth Meeting of the Regional Technical Advisory Group (RTAG), liposomal amphotericin B (LAMB) as single dose (10 mg/kg) (or multiple doses (15 mg/kg)) is the first choice regimen for the Indian subcontinent (ISC) in the attack phase. The combination regimens (LAMB/paromomycin, LAMB/miltefosine, and paromomycin/miltefosine) have been recommended as a second choice regimen, and to be used as a long-term strategy. Monotherapy with miltefosine was recommended to be

预览已结束, 完整报告链接

https://www.yunbaogao.cn/report/index/repo